Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. 
Twelve patients with primary biliary cirrhosis (PBC), stages I to III, received long-term therapy with a combination of 600 mg ursodeoxycholic acid (UDCA) and 1 mg colchicine given daily for more than 2 years.  Drug toxicity was mild; one patient experienced diarrhoea that was probably due to colchicine.  Serum levels of bilirubin, alkaline phosphatase (ALPase), gamma-glutamyl transpeptidase and alanine aminotransferase decreased by more than 50% of the initial values.  Serum albumin and cholesterol levels also improved, but immunoglobulins and anti-mitochondrial antibody titre did not change.  Histologic features in the eight patients who received serial liver biopsies before and 2 years after the beginning of treatment were evaluated.  Piecemeal necrosis and portal inflammation were improved, but there was no change in portal fibrosis.  Patients were divided into two groups; the first received both drugs from the outset, and the second group were started on UDCA for 3 months followed by the addition of colchicine.  After 3 months, the improvement in serum bilirubin and ALPase in the first group was greater than in the second.  However, in the second group, the ALPase levels had decreased significantly when measured at 6 and 9 months after the treatment compared with the levels at 3 months.  These findings suggest that UDCA and colchicine may have a synergistic effect.  This combination therapy appears to be safe and effective, both clinically and histologically, for treating PBC.